FIELD OF INVENTION
[0001] The present invention relates to novel 1,3-dioxane carboxylic acids of the general
formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable
salts, pharmaceutical compositions containing them, methods for their preparation,
use of these compounds in medicine and the intermediates involved in their preparation.
[0002] The compounds of the general formula (I) lower blood glucose, lower or modulate triglyceride
levels and/or cholesterol levels and/or low-density lipoproteins (LDL) and raises
the high-density lipoproteins (HDL) plasma levels and hence are useful in combating
different medical conditions, where such lowering (and raising) is beneficial. Thus,
it could be used in the treatment and/or prophylaxis of obesity, hyperlipidaemia,
hypercholesteremia, hypertension, atherosclerotic disease events, vascular restenosis,
diabetes and many other related conditions.
[0003] The compounds of general formula (I) are useful to prevent or reduce the risk of
developing atherosclerosis, which leads to diseases and conditions such as artereosclerotic
cardiovascular diseases, stroke, coronary heart diseases, cerebrovascular diseases,
peripheral vessel diseases and related disorders.
[0004] These compounds of general formula (I) are useful for the treatment and/or prophylaxis
of metabolic disorders loosely defined as Syndrome X. The characteristic features
of Syndrome X include initial insulin resistance followed by hyperinsulinemia, dyslipidemia
and impaired glucose tolerance. The glucose intolerance can lead to non-insulin dependent
diabetes mellitus (NIDDM, Type 2 diabetes), which is characterized by hyperglycemia,
which if not controlled may lead to diabetic complications or metabolic disorders
caused by insulin resistance. Diabetes is no longer considered to be associated only
with glucose metabolism, but it affects anatomical and physiological parameters, the
intensity of which vary depending upon stages/duration and severity of the diabetic
state. The compounds of this invention are also useful in prevention, halting or slowing
progression or reducing the risk of the above mentioned disorders along with the resulting
secondary diseases such as cardiovascular diseases, like arteriosclerosis, atherosclerosis;
diabetic retinopathy, diabetic neuropathy and renal disease including diabetic nephropathy,
glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis
and end stage renal diseases, like microalbuminuria and albuminuria, which may be
result of hyperglycemia or hyperinsulinemia.
[0005] The compounds of the present invention can be useful as aldose reductase inhibitors;
for improving cognitive functions in dementia, and in the treatment and/or prophylaxis
of disorders such as psoriasis, polycystic ovarian syndrome (PCOS), cancer, osteoporosis,
leptin resistance, inflammation and inflammatory bowel diseases, xanthoma, pancreatitis,
myotonic dystrophy, endothelial cell dysfunction and hyperlipidemia.
BACKGROUND OF THE INVENTION
[0006] Hyperlipidemia has been recognized as the major risk factor in causing cardiovascular
diseases due to atherosclerosis. Atherosclerosis and other such peripheral vascular
diseases affect the quality of life of a large population in the world. The therapy
aims to lower the elevated plasma LDL cholesterol, low-density lipoprotein and plasma
triglycerides in order to prevent or reduce the risk of occurrence of cardiovascular
diseases. The detailed etiology of atherosclerosis and coronary artery diseases is
discussed by
Ross and Glomset [New Engl. J. Med., 295, 369-377 (1976)]. Plasma cholesterol is generally found esterified with various serum lipoproteins
and numerous studies have suggested an inverse relationship between serum HDL-cholesterol
level and risk for occurrence of cardiovascular disease. Many studies have suggested
an increased risk of coronary artery diseases (CAD) due to elevated LDL and VLDL-cholesterol
levels [
Stampfer et al., N. Engl. J. Med., 325, 373-381(1991)]. The other studies illustrate protective effects of HDL against progression of
atherosclerosis. Thus, HDL has become a crucial factor in treating diseases with increased
levels of cholesterol [
Miller et. al., Br. Med. J. 282, 1741-1744(1981);
Picardo et al., Arteriosclerosis, 6, 434-441 (1986);
Macikinnon et al., J. Biol. Chem. 261, 2548-2552 (1986)].
[0007] Diabetes is associated with a number of complications and also affect a large population.
This disease is usually associated with other diseases such as obesity, hyperlipidemia,
hypertension and angina. It is well established that improper treatment can aggravate
impaired glucose tolerance and insulin resistance, thereby leading to frank diabetes.
Further, patients with insulin resistance and type 2 diabetes often have raised triglycerides
and low HDL-cholesterol concentrations and therefore, have greater risk of cardiovascular
diseases. The present therapy for these diseases includes sulfonylureas and biguanides
along with insulin. This type of drug therapy may lead to mild to severe hypoglycemia,
which may lead to coma or in some cases may lead to death, as a result of unsatisfactory
glycemic control by these drugs. Recent addition of drugs in the treatment of diabetes
are the thiazolidinediones, drugs having insulin-sensitizing action. Thiazolidinediones
like troglitazone, rosiglitazone and pioglitazone are prescribed alone or in combination
with other anti-diabetic agents.
[0008] These are useful in treating diabetes, lipid metabolism but are suspected to have
tumor-inducing potential and cause hepatic dysfunction, which may lead to liver failure.
Further, serious undesirable side-effects have occurred in animal and/or human studies
which include cardiac hypertrophy, haemodilution and liver toxicity in a few glitazones
progressing to advanced human trials. The drawback is considered to be idiosyncratic.
Presently, there is a need for a safe and an effective drug, to treat insulin resistance,
diabetes and hyperlipidemia.[
Exp. Clin. Endocrinol. Diabetes: 109(4), S548-9 (2001)]
[0009] Obesity is another major health problem being associated with increased morbidity
and mortality. It is a metabolic disorder, in which excess of fat is accumulated in
the body. Although, its etiology is unclear, the general feature includes excess of
calorie intake than it is consumed. Various therapies such as dieting, exercise, appetite
suppression, inhibition of fat absorption etc. have been used to combat obesity. However,
more efficient therapies to treat this abnormality is essential as obesity is closely
related to several diseases such as coronary heart disease, stroke, diabetes, gout,
osteoarthritis, hyperlipidemia and reduced fertility. It also leads to social and
psychological problems [
Nature Reviews: Drug Discovery: 1(4), 276-86 (2002)].
[0010] Peroxisome Proliferator Activated Receptor (PPAR) is a member of the steroid/retinoid/
thyroid hormone receptor family. PPAR∝, PPARγ and PPARδ have been identified as subtypes
of PPARs. Extensive reviews regarding PPAR, their role in different diseased conditions
are widely published [
Endocrine Reviews, 20(5), 649-688 (1999);
J. Medicinal Chemistry, 43(4), 58-550 (2000);
Cell, 55, 932-943 (1999);
Nature, 405, 421-424 (2000);
Trends in Pharmacological Sci., 469-473 (2000)]. PPARγ activation has been found to play a central role in initiating and regulating
adipocyte differentiation [
Endocrinology 135, 798-800, (1994)] and energy homeostasis, [
Cell, 83, 803-812 (1995);
Cell, 99, 239-242 (1999)]. PPARγ agonists would stimulate the terminal differentiation of adipocyte precursors
and cause morphological and molecular changes characteristic of a more differentiated,
less malignant state. During adipocyte differentiation, several highly specialized
proteins are induced, which are being involved in lipid storage and metabolism. It
is accepted that PPARγ activation leads to expression of CAP gene [
Cell Biology, 95, 14751-14756, (1998)], however, the exact link from PPARγ activation to changes in glucose metabolism
and decrease in insulin resistance in muscle has not been clear. PPARα is involved
in stimulating β-oxidation of fatty acids [
Trends Endocrine. Metabolism, 4, 291-296 (1993)] resulting in plasma circulating free fatty acid reduction [
Current Biol., 5, 618-621 (1995)]. Recently, role of PPARγ activation in the terminal differentiation of adipocyte
precursors has been implicated in the treatment of cancer. [
Cell, 79, 1147-1156 (1994);
Cell, 377-389 (1996);
Molecular Cell, 465-470 (1998);
Carcinogenesis, 1949-1953 (1998);
Proc. Natl. Acad Sci., 94, 237-241 (1997);
Cancer Research, 58, 3344-3352 (1998)]. Since PPARγ is expressed in certain cells consistently, PPARγ agonists would lead
to nontoxic chemotherapy. There is growing evidence that PPAR agonists may also influence
the cardiovascular system through PPAR receptors as well as directly by modulating
vessel wall function [
Med Res. Rev., 20 (5), 350-366 (2000)].
[0011] PPAR α agonists have been found useful in the treatment of obesity (
WO 97/36579). Dual PPAR α and γ agonists have been suggested to be useful for Syndrome X (
WO 97/25042). PPAR γ agonists and HMG-CoA reductase inhibitors have exhibited synergism and indicated
the usefulness of the combination in the treatment of atherosclerosis and xanthoma
(
EP 0753298).
[0012] Leptin is a protein when bound to leptin receptors is involved in sending satiety
signal to the hypothalamus. Leptin resistance would therefore lead to excess food
intake, reduced energy expenditure obesity, impaired glucose tolerance and diabetes
[
Science, 269, 543-46(1995)]. It has been reported that insulin sensitizers lower plasma leptin concentration
[
Proc. Natl. Acad Sci. 93, 5793-5796 (1996):
WO 98/02159)].
[0013] Several compounds have been reported which are dual agonists of PPAR α and γ like
alkoxy phenyl propanoic acid derivatives, aryloxy propanoic acid derivatives, benzyl
glycine derivatives etc have been reported and are in various developmental stages.
[0014] WO 2005077943 discloses 1,3-dioxane derivatives useful in the treatment of obesity and diabetes.
[0015] US 20030166697 (Nippon Shinayaku) discloses compounds of the following general formula:
R
1-Het-D-E
wherein
R
1 represents (un)substituted aryl, aromatic heterocyclic or cycloalkyl groups; 'Het'
is an optionally substituted divalent aromatic heterocyclic group; W is -CH- or N;
m = 1-10; n = 0-9; p = 0-2; Y = O or S; R
3 is H or alkyl; Z =carboxy, alkoxy carbonyl etc.
[0016] WO 2000004011 discloses compounds having the following general formula for the treatment of dyslipidemia,
atherosclerosis and diabetes;
where X; Y = CH
2, O, S, NR
a (R
a = H, alkyl, aryl, etc.); R = H, alkyl, cycloalkyl, etc.; R
1 = H, alkyl, hydroxyalkyl, -(CH
2)
t-COOR
c where t = 0-6 & R
c represents H or alkyl group, etc.; R
2 & R
3 = H, alkyl, cycloalkyl, (C
6-C
10)aryl, (C
6-C
10)aryl(C
1-C
7)alkyl, 3-10 membered optionally substituted heterocyclic group etc.; or R
2 & R
3 optionally form a chain -(CH
2)
r1 (r1 = 2-5), etc.; R
4-R
7 = H, alkyl, (un)substituted aryl, etc.
[0017] However, the therapeutic potential of these compounds to treat diseases has not yet
been proved and so there remains the need to develop newer medicines which are better
or of comparable efficacy with the present treatment regimes, have lesser side effects
and require a lower dosage regime
[0018] We herein disclose novel compounds of formula (I) useful as hypocholesterolemic,
hypolipidemic, hypolipoproteinemic, anti-obesity and antihyperglycemic agents which
may have additional body weight lowering effect and beneficial effect in the treatment
and/or prophylaxis of diseases caused by hyperlipidemia, diseases classified under
Syndrome X and atherosclerosis, and methods for their preparation.
PREFERRED EMBODIMENTS OF THE INVENTION
[0019] The main objective of the present invention is to provide novel substituted 1,3 dioxane
carboxylic acids and their derivatives represented by the general formula (I), their
tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, and
pharmaceutical compositions containing them or their mixtures thereof.
[0020] In an embodiment of the present invention is provided a process for the preparation
of novel substituted 1,3 dioxane carboxylic acids and their derivatives represented
by the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically
acceptable salts.
[0021] In a further embodiment of the present invention is provided pharmaceutical compositions
containing compounds of the general formula (I), their tautomeric forms, their stereoisomers,
their pharmaceutically acceptable salts, or their mixtures in combination with suitable
carriers, solvents, diluents and other media normally employed in preparing such compositions.
DETAILED DESCRIPTION OF THE INVENTION
[0022] Accordingly, the present invention relates to compounds of the general formula (I),
their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts,
and pharmaceutical compositions containing them wherein
'A' represents an optionally substituted single or fused group selected from aryl,
heteroaryl, heterocyclyl groups;
'B' represents substituted or unsubstituted linear or branched (C
1-C
6)alkyl group;
'm' represent an integer from 2-6;
R
1 represents (C
1-C
3)alkyl group
R
2 represents hydrogen, linear or branched (C
1-C
3) alkyl group.
[0023] The aryl group may be an aromatic system containing one, two or three rings wherein
such rings may be attached together in a pendant manner or may be fused; in a preferred
embodiment such aryl group may be selected from phenyl, naphthyl, tetrahydronaphthyl,
indane, biphenyl groups;
[0024] The heteroaryl group represents 5 to 8 membered aromatic radicals, which may be single
or fused containing one or more hetero atoms selected from O, N or S; in a preferred
embodiment such groups may be selected from pyridyl, thienyl, furyl, pyrrolyl, oxazolyl,
thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl,
tetrazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzothienyl, indolinyl, indolyl,
azaindolyl, azaindolinyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidinyl,
pyrazolopyrimidonyl, azaquinazolinyl, azaquinazolinoyl, pyridofuranyl, pyridothienyl,
thienopyrimidyl, thienopyrimidonyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl,
quinazolonyl, pyrimidonyl, pyridazinyl, triazinyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl,
benzothiazinonyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzotriazolyl, phthalazynil,
naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl groups;
[0025] The term "heterocyclyl" represents saturated, partially saturated and unsaturated
ring-shaped radicals, the heteroatoms selected from nitrogen, sulfur and oxygen; in
a preferred embodiment such groups may be selected from pyrrolidinyl, imidazolidinyl,
piperidinyl, piperazinyl, morpholinyl, oxazolidinyl, thiazolidinyl, and the like;
examples of partially saturated heterocyclic radicals include dihydrothiophene, dihydropyran,
dihydrofuran, dihydrothiazole groups;
[0026] When A is substituted, the substituents may be selected from hydroxyl, oxo, halo,
thio, amino, or substituted or unsubstituted groups selected from alkyl, haloalkyl,
aminoalkyl, akoxy, alkoxyalkyl, haloalkoxy, cycloalkyl, alkoxy, cycloalkoxy, aryl,
aryloxy, aralkyl, aralkoxy, heteroaryl, heteroarakyl, heteroaryloxy, acyl, acyloxy,
hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, aminocarbonyl,
arylthio, alkylsulfonyloxy, sulfenyl derivatives, sulfonyl derivatives.
[0027] When the substituents on 'A' are further substituted, those substituents are selected
from hydroxyl, oxo, halo, thio, or substituted or unsubstituted groups selected from
alkyl, haloalkyl, alkoxy, haloalkoxy, acyl, acyloxy, alkylthio, thioalkyl, alkylsulfonyloxy,
alkoxycarbonylamino, sulfenyl derivatives, sulfonyl derivatives.
[0028] The various groups, radicals and substituents used anywhere in the specification
are described in the following paragraphs.
[0029] In a further preferred embodiment the groups, radicals described above may be selected
from:
- the "alkyl" group used either alone or in combination with other radicals, denotes
a linear or branched radical containing one to six carbons, selected from methyl,
ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, amyl, t-amyl, n-pentyl, n-hexyl, n-heptyl, iso-heptyl, n-octyl, iso-octyl and the like;
- the "cycloalkyl", or "alicyclic" group used either alone or in combination with other
radicals, is selected from a cyclic radical containing three to six carbons, more
preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; The terms
"bicycloalkyl" means more than one cycloalkyl groups fused together;
- the "alkoxy" group used either alone or in combination with other radicals, is selected
from groups containing an alkyl radical, as defined above, attached directly to an
oxygen atom, more preferably groups selected from methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, t-butoxy, iso-butoxy, pentyloxy, hexyloxy, and the like;
- the "haloalkyl" group is selected from an alkyl radical, as defined above, suitably
substituted with one or more halogens; such as perhaloalkyl, more preferably, perfluoro(C1-C6)alkyl such as fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl,
trifluoroethyl, mono or polyhalo substituted methyl, ethyl, propyl, butyl, pentyl
or hexyl groups;
- the "haloalkoxy" group is selected from suitable haloalkyl, as defined above, directly
attached to an oxygen atom, more preferably groups selected from fluoromethoxy, chloromethoxy,
fluoroethoxy, chloroethoxy and the like;
- the "aryl" or "aromatic" group used either alone or in combination with other radicals,
is selected from a suitable aromatic system containing one, two or three rings wherein
such rings may be attached together in a pendant manner or may be fused, more preferably
the groups are selected from phenyl, naphthyl, tetrahydronaphthyl, indane, biphenyl,
and the like;
- the "heterocyclyl" or "heterocyclic" group used either alone or in combination with
other radicals, is selected from suitable saturated, partially saturated or unsaturated
aromatic or non aromatic mono, bi or tricyclic radicals, containing one or more heteroatoms
selected from nitrogen, sulfur and oxygen, more preferably selected from aziridinyl,
azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl,
4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl,
2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl,
dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl,
benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl,
quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl,
thieno piperidinyl, and the like; the "heteroaryl" or "heteroaromatic" group used
either alone or in combination with other radicals, is selected from suitable single
or fused mono, bi or tricyclic aromatic heterocyclic radicals containing one or more
hetero atoms selected from O, N or S, more preferably the groups are selected from
pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl,
isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl,
indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl,
pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl,
quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl; phthalazynil,
naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl
and the like;
- the groups "heteroaryloxy", "heteroaralkoxy", "heterocycloxy", "heterocylylalkoxy"
are selected from suitable heteroaryl, heteroarylalkyl, heterocyclyl, heterocylylalkyl
groups respectively, as defined above, attached to an oxygen atom;
- the term "aralkyl" refers to an aryl group as defined above, directly attached to
an alkyl group as defined above, at one or more positions;
- the term "aralkoxy" refers to an aralkyl group, as defined above attached directly
to an oxygen atom;
- the terms "cycloalkoxy" and "aryloxy" refers to a cycloalkyl group and an aryl group
respectively, as defined above, attached directly to an oxygen atom;
- the term "heteroaralkyl" used herein, either alone or in combination with other radicals,
denotes a heteroaryl group, as defined above, attached to a straight or branched saturated
carbon chain containing 1 to 6 carbons, such as (2-furyl)methyl, (3-furyl)methyl,
(2-thienyl)methyl, (3-thienyl)methyl, (2-pyridyl)methyl, 1-methyl-1-(2-pyrimidyl)ethyl
and the like;
- the term "aryloxyalkyl" used herein, alone or in combination with other radicals,
includes phenoxymethyl, napthyloxymethyl, and the like;
- the term "aralkoxyalkyl" used herein, alone or in combination with other radicals,
includes C6H5CH2OCH2, C6H5CH2OCH2CH2, and the like;
- the term "arylthio' used herein, either alone or in combination with other radicals,
refers to an aryl group, as defined above, linked through a divalent sulfur atom,
having a free valence bond from the sulfur atom such as phenylthio, napthylthio and
the like;
- the "acyl" group used either alone or in combination with other radicals, is selected
from a radical containing one to eight carbons, more preferably selected from formyl,
acetyl, propanoyl, butanoyl, iso-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl
and the like, which may be substituted;
- the "acyloxy" group used either alone or in combination with other radicals, is selected
from a suitable acyl group, as defined above, directly attached to an oxygen atom,
more preferably such groups are selected from acetyloxy, propionyloxy, butanoyloxy,
iso-butanoyloxy, benzoyloxy and the like;
- the "oxo" or "carbonyl" group used either alone (-C=O-) or in combination with other
radicals such as alkyl described above, for e.g. "alkylcarbonyl", denotes a carbonyl
radical (-C=O-) substituted with an alkyl radical described above such as acyl or
alkanoyl;
- the "carboxylic acid" group, used alone or in combination with other radicals, denotes
a -COOH group, and includes derivatives of carboxylic acid such as esters and amides;
- the "ester" group used alone or in combination with other radicals, denotes -COO-group,
and includes carboxylic acid derivatives, more preferably the ester moieties are selected
from alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, and the like, which
may optionally be substituted; aryloxycarbonyl group such as phenoxycarbonyl, napthyloxycarbonyl,
and the like, which may optionally be substituted; aralkoxycarbonyl group such as
benzyloxycarbonyl, phenethyloxycarbonyl, napthylmethoxycarbonyl, and the like, which
may optionally be substituted; heteroaryloxycarbonyl, heteroaralkoxycarbonyl, wherein
the heteroaryl group, is as defined above, which may optionally be substituted; heterocyclyloxycarbonyl,
where the heterocyclic group, as defined earlier, which may optionally be substituted;
- the "aminocarbonyl" group used either alone or in combination with other radicals,
may be selected from 'aminocarbonyl', 'aminocarbonylalkyl", "n-alkylaminocarbonyl",
"N-arylaminocarbonyl", "N,N-dialkylaminocarbonyl", "N-alkyl-N-arylaminocarbonyl",
"N-alkyl-N-hydroxyaminocarbonyl", and "N-alkyl-N-hydroxyaminocarbonylalkyl", each
of them being optionally substituted. The terms "N-alkylaminocabonyl" and "N,N-dialkylaminocarbonyl"
denotes aminocarbonyl radicals, as defined above, which have been substituted with
one alkyl radical and with two alkyl radicals, respectively. Preferred are "lower
alkylaminocarbonyl" having lower alkyl radicals as described above attached to aminocarbonyl
radical. The terms "N-arylaminocarbonyl" and "N-alkyl-N-arylaminocarbonyl" denote
amiocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl,
and one aryl radical. The term "aminocarbonylalkyl" includes alkyl radicals substituted
with aminocarbonyl radicals;
- the "hydroxyalkyl" group used either alone or in combination with other radicals,
is selected from an alkyl group, as defined above, substituted with one or more hydroxy
radicals, more preferably the groups are selected from hydroxymethyl, hydroxyethyl,
hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like;
- the "aminoalkyl" group used alone or in combination with other radicals, denotes an
amino (-NH2) moiety attached to an alkyl radical, as defined above, which may be substituted,
such as mono- and di-substituted aminoalkyl. The term "alkylamino" used herein, alone
or in combination with other radicals, denotes an alkyl radical, as defined above,
attached to an amino group, which may be substituted, such as mono- and di-substituted
alkylamino;
- the "alkoxyalkyl," group used alone or in combination with other radicals, denotes
an alkoxy group, as defined above, attached to an alkyl group as defined above, more
preferably the groups may be selected from methoxymethyl, ethoxymethyl, methoxyethyl,
ethoxyethyl and the like;
- the "alkylthio" group used either alone or in combination with other radicals, denotes
a straight or branched or cyclic monovalent substituent comprising an alkyl group
as defined above, linked through a divalent sulfur atom having a free valence bond
from the sulfur atom, more preferably the groups may be selected from methylthio,
ethylthio, propylthio, butylthio, pentylthio and the like or cyclic alkylthio selected
from cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio and the like,
which may be optionally substituted;
- the "thioalkyl" group used either alone or in combination with other radicals, denotes
an alkyl group, as defined above, attached to a group of formula -SR', where R' represents
hydrogen, alkyl or aryl group, e.g. thiomethyl, methylthiomethyl, phenylthiomethyl
and the like, which may be optionally substituted.
- the "alkoxyamino" group used either alone or in combination with other radicals, represents
a suitable alkoxy group as defined above, attached to an amino group;
- the "hydroxyamino" group used either alone or in combination with other radicals,
represents a -NHOH moiety, and may be optionally substituted with suitable groups
selected from those described above;
- the "sulfenyl" group or "sulfenyl derivatives" used alone or in combination with other
radicals, represents a bivalent group, -SO- or RxSO, where Rx is an optionally substituted alkyl, aryl, heteroaryl, heterocyclyl, group selected
from those described above;
- the "sulfonyl" group or "sulfones derivatives" used either alone or in combination
with other radicals, with other terms such as alkylsulfonyl, represents a divalent
radical -SO2-, or RxSO2-, where Rx is as defined above. More preferably, the groups may be selected from "alkylsulfonyl"
wherein suitable alkyl radicals, selected from those defined above, is attached to
a sulfonyl radical, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl and the
like, "arylsulfonyl" wherein an aryl radical, as defined above, is attached to a sulfonyl
radical, such as phenylsulfonyl and the like;
- the "alkylsulfonyloxy" group used either alone or in combination, refers to an alkylsulfonyl
group as defined above, attached directly to an oxygen atom.
[0030] Suitable groups and substituents on the groups may be selected from those described
anywhere in the specification.
Particularly useful compounds may be selected from
Methyl-2-methyl-5-[4-(1-phenyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-[4-(1-phenyl-pentylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
Methyl-5-(4-benzylideneaminooky-butyl)-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-{4-[1-(4-trifluoromethyl-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-chloro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-methanesulfonyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3,]dioxane-2-carboxylate;
Methyl-(2-methyl-5-[4-(1-m-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-)-2-carboxylate.
Methyl-5-{4-[1-(4-butyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-[4-(1-p-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-{4-[1-(4-methylsulfanyl-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-ethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-ethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-isopropoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-{4-[1-(4-phenoxy-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-caiboxylate;
Methyl-5-{4-[1-(4-isobutyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-[4-(1-biphenyl-4-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(3-chloro-4-fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(3,4-dimethyl-phenyl)-emylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{5-[1-(3,4-dimethyl-phenyl)-ethylideneaminooxy]-pentyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-methoxy-3-methyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(3,4-dimethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(3-Fluoro-4-methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-(5-{4-[1-(4-methoxy-phenyl)-propylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-)-
2-carboxylate;
Methyl-{2-methyl-5-[4-(1-p-tolyl-propylideneaminooxy)-butyl]-[1,3]dioxane}-2-carboxylate;
Methyl-{2-methyl-5-[4-(1-pyridin-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-}-2-carboxylate;
Methyl-{2-methyl-5-[4-(1-pyridin-3-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-}-2-carboxylate;
Methyl-{2-methyl-5-[4-(1-pyridin-4-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-}-2-carboxylate;
Methyl-5-[4-(1-benzo[1,3]dioxol-5-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-[4-(1-thiophen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
Methyl-5-[4-(1-benzofuran-2-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylate;
Methyl-5-[5-(1-benzofuran-2-yl-ethylideneaminooxy)-pentyl]-2-methyl-[1,3]dioxane-2-carboxylate;
Methy-5-{4-[1-(2,3-dimethyl-benzofuran-6-yl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate;
Mcthyl-2-methyl-5-{4-[1-(1-methyl-1H-indol-3-yl)-elhylidencaminooxy]-butyl}-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-[5-(1-naphthalen-2-yl-ethylideneaminooxy)-pentyl]-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
Methyl-2-methyl-5-{4-[1-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-methoxymethoxy-phenyl)-ethylideneaminooxy]-buty}-2-ethyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-hydroxy-phenyl)-ethylideneaminooxy]-buty}-2-ethyl-[1,3]dioxane-2-carboxylate;
Methyl-5-{4-[1-(4-methanesulfonyloxy-phenyl)-ethylideneaminooxy]-butyl -2-methyl-[1,3]dioxane-2-carboxylate;
Octyl-2-methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate;
2-Methyl-5-[4-(1-phenyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
and its pharmaceutically acceptable salts;
5-(4-Benzylideneaminooxy-butyl)-2-methyl-[1,3]dioxane-2-carboxylic acid and its pharmaceutically
acceptable salts;
2-Methyl-5-{4-[1-(4-trifluoromethyl-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Chloro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Methanesulfonyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-p-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
and its pharmaceutically acceptable salts;
5-{4-[1-(3-Chloro-4-fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Butyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-{4-[1-(4-methylsulfanyl-phenyl)-ethylideneaminoooxy]-butyl}-[1,3]dioxarie-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Ethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(3,4-Dimethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{5-[1-(3,4-Dimethyl-phenyl)-ethylideneaminooxy]-pentyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Ethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Isopropoxy-phenyl)ethylideneaminooxy]-buty}-2-ethyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[-(4-Methoxy-3-methyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-{4-[1-(4-phenoxy-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(3,4-Dimethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Isobutyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid;
5-{4-[1-(3-Fluoro-4-methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[5-(1-naphthalen-2-yl-ethylideneaminooxy)-pentyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-{4-[1-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Hydroxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(4-Methanesulfonyloxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-thiophen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-[4-(1-Betuo[1,3]dioxol-5-yl-ethylideneaminoxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-[4-(1-Biphenyl-4-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-phenyl-pentylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
and its pharmaceutically acceptable salts;
5-[4-(1-Benzofuran-2-yl-ethylidencaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-[5-(1-Benzofuran-2-yl-ethylideneaminooxy)-pentyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
5-{4-[1-(2,3-Dimethyl-benzofuran-6-yl)-ethylideneaminooxy]-buty}-2-ethyl-[1,3]dioxane-2-carboxylicacid
and its pharmaceutically acceptable salts;
2-Methyl-5-{4-[1-(1-methyl-1H-indol-3-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-m-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
and its pharmaceutically acceptable salts;
3-{4-[1-(4-Methoxy-phenyl)-propylideneaminooxy]-buty}-2-ethyl-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-p-tolyl-propylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-pyridin-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-pyridin-3-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-[4-(1-pyridin-4-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts;
2-Methyl-5-{4-[1-(5-methyl-furan-2-yl)-ethylideneaminooxy]butyl}-[1,3]dioxane-2-carboxylic
acid and its pharmaceutically acceptable salts.
The novel compounds of this invention may be prepared using the reactions and techniques
as shown in scheme below and described in this section. The reactions are performed
in solvents appropriate to the reagents and materials employed and are suitable for
the transformations being effected. It is understood by those skilled in the art that
the nature and order of the synthetic steps presented may be varied for the purpose
of optimizing the formation of the compounds of the present invention.
- i. reacting compounds of general formula (II) where all symbols are as defined earlier
with compounds of general formula (III), where all symbols are as defined earlier
and L represents a suitable leaving group such as halogen, mesylate, tosylate, triflate
& the like and R2 represent alkyl group to yield compound of general formula (I) where all symbols are as defined earlier and R2 represent alkyl group.
- ii. hydrolysis of compound of general formula (I) wherein R2 is alkyl and all other symbols are as defined earlier to yield further compound of
general formula (I) wherein R2 is H and all other symbols are as defined earlier.
- iii. the compounds of formula (I) may optionally be converted to its pharmaceutically
acceptable salts by techniques known in the art.
[0031] Step I: The compound of formula (I) may be prepared by reacting compound of formula (II)
with compound of formula (III) under suitable conditions. The reaction may be carried
out in presence of solvents such as acetone, tetrahydrofuran, dimethyl sulfoxide,
dioxane, acetonitrile, dimethyl formamide, dimethoxy ethane, benzene, toluene, petroleum
ether, heptane, hexane, 2-butanone, xylene, alcohols such as methanol, ethanol, propanol,
butanol, iso-butanol,
tert-butanol, pentanol and the like or mixtures thereof. Bases such as alkali metal carbonates
such as K
2CO
3, Na
2CO
3, CsCO
3, and the like; or alkali metal hydroxides such as NaOH, KOH and the like, may be
used during this reaction. Alkali metal hydrides such as NaH, KH can be used whenever
solvent employed is not protic or contain carbonyl group. The reaction may be carried
out at a temperature in the range 0 °C to reflux temperature of the solvent(s) used
and the reaction time may range from 1 to 48 hours.
[0032] Step II: The compound of formula
(I) may be hydrolysed to further compound of formula
(I) using suitable base e.g., NaOH, LiOH, KOH and the like. Reaction may be conducted
in suitable solvents e.g., alcohols like methanol, ethanol and the like, THF, water
or the mixtures thereof. The reaction may be carried out at a temperature in the range
20 °C to reflux temperature of the solvent(s) used and the reaction time may range
from 1 to 48 hours.
The invention is explained in greater detail by the examples given below, which are
provided by way of illustration only and therefore should not be construed to limit
the scope of the invention.
1H NMR spectral data given in the examples (vide infra) are recorded using a 300 MHz
spectrometer (Bruker AVANCE-300) and reported in δ
scale. Until and otherwise mentioned the solvent used for NMR is CDCl3 using tetramethyl silane as the internal standard.
Example 1
Methyl-2-methyl-5-[4-(1-phenyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate
[0033] A mixture of 1-Phenyl-ethanone oxime (1.13 g), Methyl-5-(4-chloro-butyl)-2-methyl-[1,3]dioxane-2-carboxylate
(prepared by processes known) (2.5 g) and cesium carbonate (4.0 g) in anhydrous dimethyl
formamide was stirred at 60 °C for 18 hours in an inert atmosphere. The reaction mixture
was cooled to ambient temperature, poured into ice cold water and extracted with ethyl
acetate. The combined organic extract was washed with water, brine solution, dried
over sodium sulphate and evaporated under reduced pressure. Crude product was flash
chromatographed over silica gel using 7% ethyl acetate in petroleum ether as eluent
to obtain 2.5 g of pure product.
1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=12.5 Hz), 3.8 (3H, s), 3.9 (2H, dd, J=12.0 & 4.6 Hz), 4.1 (2H, t, J=6.4
Hz), 7.3 (3H, m), 7.6 (2H, m). Yield: 85 %
[0034] The following compounds are prepared by procedure similar to that described in example
1 with appropriate variations of reactants, reaction conditions and quantities of
reagents.
Example 2
Methyl-2-methyl-5-[4-(1-phenyl-pentylideneaminoogy)-butyl]-[1,3]dioxane-2-carboxylate
[0035] 1H NMR: 0.9 (3H, t, J=7.2 Hz), 1.0 (2H, m), 1.4 (4H, m), 1.5 (5H, m), 1.7 (2H, m),
2.0 (1H, m), 2.7 (2H, t, J=7.4 Hz), 3.4 (2H, t, J=11.5 Hz), 3.8 (3H, s), 4.0 (2H,
dd, J=12.1 & 4.9 Hz), 4.2 (2H, t, J=6.4 Hz), 7.3 (3H, m), 7.6 (2H, m). Yield: 54 %
Example 3
Methyl-5-(4-benzylideneaminooxy-butyl)-2-methyl-[1,3]dioxane-2-carbozylate
[0036] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.73 (2H, m), 2.0 (1H, m), 3.4 (2H,
t, J=11.7 Hz), 3.8 (3H, s), 3.9 (2H, dd, J=12.1 & 4.6 Hz), 4.1 (2H, t, J=6.4 Hz),
7.3 (3H, m), 7.5 (2H, m), 8.0 (1H, s). Yield: 82 %
Example 4
Methyl-2-methyl-5-{4-[1-(4-trifluoromethyl-phenyl)ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate
[0037] 1H NMR: 1.0 (2H, m), 1.3 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.8 Hz), 3.8 (3H, s), 4.0 (2H, dd, J=12.1 & 4.6 Hz), 4.2 (2H, t, J=6.5
Hz), 7.6 (2H, d, J=8.3 Hz), 7.7 (2H, d, J=8.2 Hz ). Yield: 47 %
Example 5
Methyl-5-{4-[1-(4-nuoro-phenyl)ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0038] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.5 Hz), 3.8 (3H, s), 3.9 (2H, dd, J=12.0 & 4.6 Hz), 4.1 (2H, t, J=6.4
Hz), 7.0 (2H, m), 7.6 (2H, m). Yield: 79 %
Example 6
Methyl-5-{4-[1-(4-chloro-phenyl)-ethylideneaminoogy]-butyl}-2-methyl-[1,3]oxane-2-carboxylate
[0039] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.7 Hz), 3.8 (3H, s), 3.9 (2H, dd, J=12.0 & 4.6 Hz), 4.1 (2H, t, J=6.4
Hz), 7.3 (2H, dd, J=6.7 & 2.0 Hz), 7.6 (2H, dd, J=6.7 & 1.9 Hz). Yield: 86 %
Example 7
Methyl-5-{4-[1-(4-methanesulfonyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0040] 1H NMR: 1.12 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H,
s), 3.0 (3H, s), 3.4 (2H, t, J=11.7 Hz), 3.8 (3H, s), 4.0 (2H, dd, J=12.0 & 4.6 Hz),
4.2 (2H, t, J=6.4 Hz), 7.8 (2H, dd, J=6.9 & 1.8 Hz), 7.9 (2H, d, J=8.5 Hz). Yield:
66 %
Example 8
Methyl-(2-methyl-5-[4-(1-m-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-)-2-carboxylate
[0041] 1H NMR: 1.0 (2H, m), 1.37 (2H, m), 1.51 (3H, s), 1.67 (2H, m), 2.06 (1H, m), 2.2 (3H,
s), 2.37 (3H, s), 3.4 (2H, t, J = 11.5 Hz),3.83 (3H, s), 3.98 (2H, dd, J = 4.38 &
11.7 Hz), 4.1 (2H, t, J = 6.43Hz), 7.1 (2H, m), 7.4 (2H, m). Yield: 49 %
Example 9
Methyl-5-{4-[1-(4-butyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]diozane-2-carboxylate
[0042] 1H NMR: 0.91 (3H, t, J=7.26 Hz), 1.07 (2H, m), 1.36 (4H, m), 1.51(3H, s), 1.60 (2H,
m), 1.68 (2H, m), 2.04 (1H, m), 2.19 (3H, s), 2.61 (2H, ,t, J=7.53 Hz), 3.40 (2H,
t, J=11.58 Hz), 3.82 (3H, s), 3.97 (2H, dd, J=11.88 & 4.5 Hz), 4.14 (2H, t, J= 6.39
Hz), 7.16 (2H, d, J=8.1 Hz), 7.53 (2H, d, J=8.07 Hz). Yield: 46 %
Example 10
Methyl-2-methyl-5-[4-(1-p-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate
[0043] 1H NMR: 1.04-1.11 (2H, m), 1.37-1.40 (2H, m) , 1.51 (3H, s), 1.64-1.71 (2H, m) 2.09
(1H, m), 2.19 (3H, s), 2.35 (3H, s), 3.40 (2H, t, J=11.61 Hz), 3.82 (3H, s), ,3.96
(2H, dd, J= 12.06 & 4.65 Hz), 4.14 (2H, t, J=7.42 Hz), 7.16 (2H, d , J =6.27 Hz),
7.52 (2H, d, J=8.13 Hz). Yield: 52 %
Example 11
Methyl-2-methyl-5-{4-[1-(4-methylsulfanyl-phenyl)-ethylideneaminoogy]-butyl}-[1,3]dioxane-2-carboxylate
[0044] 1H NMR: 1.04-1.11 (2H, m), 1.34-1.42 (2H, m), 1.51 (3H, s), 1.66-1.71 (2H, m) 2.08
(1H, m), 2.38 (3H, s), 2.49 (3H, s), 3.40 (2H, t, J=11.67 Hz), 3.82 (3H, s), 3.96
(2H, dd, J= 12.03 & 4.56 Hz), 4.14 (2H, t, J=6.42 Hz), 7.22 (2H, d , J =8.4 Hz), 7.55
(2H, d, J=8.4 Hz). Yield: 58 %
Example 12
Methyl-5-{4-[1-(4-ethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0045] 1H NMR: 1.06-1.11 (2H, m), 1.23 (3H, t, J= 7.59 Hz) ,1.34-1.40 (2H, m), 1.51 (3H, s),
1.69 (2H, m), 2.00 (1H, m), 2.20 (3H, s), 2.64 (2H, q, J= 15.18 & 7.62 Hz), 3.40 (2H,
t, J=11.76 Hz), 3.83 (3H, s), 3.97 (2H, dd, J=12.09 & 4.68 Hz), 4.14 (2H, t, J=6.45
Hz), 7.18 (2H, d, J= 8.25 Hz), 7.55 (2H, d, J= 1.74 Hz). Yield: 54 %
Example 13
Methyl-5-{4-[1-(4-ethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0046] 1H NMR: 1.09 (2H, m), 1.3(2H, m), 1.4 (3H, t, J=6.9 Hz), 1.51 (3H, m), 1.68 (2H, m),
2.04 (1H, m), 2.18 (3H, s), 3.40 (2H, t, J=11.67 Hz), 3.82 (3H, s), 3.96 (2H, dd,
J=12.03 & 4.53 Hz), 4.04 (2H, q, J= 13.98 & 6.99 Hz), 4.13 (2H, t, J=6.42 Hz), 6.86
(2H, d, J= 8.76 Hz), 7.56 (2H, d, J=8.76 Hz), Yield: 38 %
Example 14
Methyl-5-{4-[1-(4-isopropoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0047] 1H NMR: 1.05 (2H, m), 1.32 (3H, s), 1.34 (3H, s), 1.4 (2H, m), 1.51 (3H, s), 1.66 (2H,
m), 2.04 (1H, m), 2.18 (3H, s), 3.40 (2H, t, J=11.64 Hz), 3.82 (3H, s), 3.96 (2H,
dd, J=11.94 & 4.56 Hz), 4.13 (2H, t, J= 6.42 Hz), 4.56 (1H, m), 6.86 (2H, d, J= 8.76
Hz), 7.56 (2H, d, J=8.76 Hz). Yield: 47 %
Example 15
Methyl-2-methyl-5-{4-[1-(4-phenoxy-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate
[0048] 1H NMR: 1.04-1.11 (2H, m), 1.34-1.40 (2H, m), 1.51 (3H, s), 1.64-1.73 (2H, m), 2.05
(1H, m), 2.20 (3H, s), 3.40 (2H, t, J=11.61 Hz), 3.83 (3H, s), 3.96 (2H, dd, J= 1.2.09
& 4.65 Hz), 4.15 (2H, t, J= 6.42 Hz), 6.97-7.03 (4H, m), 7.12 (1H, m), 7.32-7.37 (2H,
m), 7.60 (2H, dd, J=6.81 & 2.01 Hz). Yield: 58 %
Example 16
Methyl-5-{4-[1-(4-isobutyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0049] 1H NMR: 0.88 (3H,s), 0.90 (3H, s), 1.06- 1.11 (2H, m), 1.37 (2H, m), 1.51 (3H, s) ,
1.66-1.71 (2H, m), 1.84 (1H, m), 2.04 (1H, m), 2.20 ( 3H, s), 2.47 (2H, d, J=7.17
Hz), 3.40 (2H, t, J=11.67 Hz), 3.83 (3H, s), 3.97 (2H, dd, J= 12.06 & 4.68 Hz), 4.15
(2H, t, J= 6.24 Hz), 7.12-7.15 (2H, d, J=8.22 Hz), 7.52-7.55 (2H, d, J=8.22 Hz). Yield:
50 %
Example 17
Methyl-5-{4-[1-(4-methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0050] 1H NMR: 1.04-1.11 (2H, m), 1.34-1.40 (2H, m) , 1.51 (3H, s), 1.64-1.71 (2H, m) 2.04
(1H, m), 2.19 (3H, s), 3.40 (2H, t, J= 11.61 Hz), 3.82 (3H, s), 3.83 (3H, s) 3.96
(2H, dd, J=12.06 & 4.68 Hz), 4.13 (2H, t, J=6.42 Hz), 7.87-6.91 (2H, m), 7.56-7.60
(2H, m). Yield: 43 %
Example 18
Methyl-5-[4-(1-biphenyl-4-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylate
[0051] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.7 Hz), 3.8 (3H, s), 4.0 (2H, dd, J=12.1 & 4.7 Hz), 4.2 (2H, t, J=6.4
Hz), 7.3 (1H, m), 7.4 (2H, m), 7.6 (4H, m), 7.7 (2H, m). Yield: 67 %
Example 19
Methyl-5-{4-[1-(3-chloro-4-fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0052] 1H NMR: 1.04-1.12 (2H, m), 1.34-1.39 (2H, m), 1.51 (3H, s), 1.64-1.71 (2H, m), 2.04
(1H, m), 2.18 ( 3H, s), 3.40 (2H, t, J=11.7 Hz), 3.83 (3H, s), 3.96 (2H, dd, J= 12.03&
4.62 Hz), 4.15 (2H, t, J= 6.45 Hz), 7.1 (1H, t, J=8.7 Hz), 7.47-7.53 (1H, m), 7.69-7.72
(1H, dd, J=7.17 & 2.4 Hz). Yield: 39 %
Example 20
Methyl-5-{4-[1-(3,4-dimethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0053] 1H NMR: 1.04- 1.11 (2H, m), 1.34-1.40 (2H, m), 1.51 (3H, s), 1.56-1.71 (2H, m), 2.05
(1H, m), 2.19 ( 3H, s), 2.26 (3H, s), 2.27 (3H, s), 3.40 (2H, t, J=11.73 Hz), 3.83
(3H, s), 3.96 (2H, dd, J= 12.27 & 4.68 Hz), 4.14 (2H, t, J= 6.45 Hz), 7.12 (1H, d,
J=7.89 Hz), 7.33 (1H, dd, J= 7.83 &1.71 Hz), 7.41 (1H, s). Yield: 45 %
Example 21
Methyl-5-{5-[1-(3,4-dimethyl-phenyl)-ethylideneaminooxy]-pentyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0054] 1H NMR: 1.02-1.07 (2H, m), 1.25-1.37 (4H, m), 1.51 (3H, s), 1.64-1.71 (2H, m), 2.02
(1H, m), 2.19 (3H, s), 2.26 (3H, s), 2.27 (3H, s), 3.40 (2H, t, J=11.64 Hz), 3.83
(3H, s), 3.96 (2H, dd, J= 12.03 & 4.62 Hz), 4.14 (2H, t, J= 6.57 Hz), 7.12 (1H, d,
J=7.86 Hz), 7.34 (1H, d, J=7.83 Hz), 7.41 (1H, s). Yield: 48 %
Example 22
Methyl-5-{4-[1-(4-methoxy-3-methyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0055] 1H NMR: 1.06-1.11 (2H, m), 1.34-1.40 (2H, m), 1.51 (3H, s), 1.57-1.71 (2H, m), 2.05
(1H, m), 2.18 (3H, s), 2.22 (3H, s), 3.40 (2H, t, J=11.73 Hz), 3.83 (3H, s), 3.84
(3H,s), 3.99 (2H, dd, J= 13.95 & 6.51 Hz), 4.13 (2H, t, J= 6.45 Hz), 6.79 ( 1H, d,
J=8.46 Hz), 7.39-7.45 (2H, m,). Yield: 54 %
Example 23
Methyl-5-{4-[1-(3,4-dimethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0056] 1H NMR: 1.04-1.12(2H, m), 1.33-1.40 (2H, m) , 1.51 (3H, s), 1.64-1.71 (2H, m) 2.05
(1H, m), 2.19 (3H, s), 3.40 (2H, t, J= 11.64 Hz) , 3.83 (3H, s), 3.90 (3H, s), 3.92
(3H, s), 3.97 (2H, dd, J=12.06 & 4.68 Hz), 4.15 (2H, t, J=6.42 Hz), 6.85 (1H, d, J=8.52
Hz), 7.13 (1H, dd, J= 8.37& 2.04 Hz), 7.27(1H, d, J= 2.01Hz). Yield: 47 %
Example 24
Methyl-5-{4-[1-(3-Fluoro-4-methoxy-phenyl)-ethytideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0057] 1H NMR: 1.04-1.11 (2H, m), 1.34-1.39 (2H, m), 1.51 (3H, s), 1.65-1.71 (2H, m), 2.04
(1H, m), 2.17 ( 3H, s), 3.40 (2H, t, J=11.67 Hz), 3.83 (3H, s), 3.90 (3H, s), 3.96
(2H, dd, J= 12.06 & 4.65 Hz), 4.14 (2H, t, J= 6.45 Hz), 6.93 ( 1H, t, J= 8.64 Hz),
7.31-7.35 (1H, m), 7.42-7.47 (1H, dd, J=12.75 & 2.13 Hz). Yield: 50 %
Example 25
Methyl-(5-{4-[1-(4-methoxy-phenyl)-propylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-)-2-carboxylate
[0058] 1H NMR: 1.1 (5H, m), 1.4 (2H, m), 1.51 (3H, s), 1.7 (2H, m), 2.1 (1H, m), 2.7 (2H,
q, J = 7.59Hz), 3.4 (2H, t, J = 11.67 Hz), 3.8 (6H, s), 3.98 (2H, dd, J = 4.56 & 12.03
Hz), 4.1 (2H, t, J = 6.36Hz), 6.9 (2H, d, J = 8.79 Hz), 7.55 (2H, d, J = 8.79 Hz).
Yield: 35 %
Example 26
Methyl-{2-methyl-5-[4-(1-p-totyl-propylideneaminooxy)-butyl]-[1,3]dioxane}-2-carboxylate
[0059] 1H NMR: 1.1 (5H, m), 1.4 (2H, m), 1.51 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.35 (3H,
s), 2.7 (2H, q, J = 7.6Hz), 3.4 (2H, t, J = 11.56 Hz), 3.82 (3H, s), 3.95 (2H, dd,
J = 4.5 & 12.02 Hz), 4.1 (2H, t, J = 6.3 Hz), 7.15 (2H, J = 8.0 Hz), 7.5 (2H, J =
8.0 Hz).
Yield: 58 %
Example 27
Methyl-{2-methyl-5-[4-(1-pyridin-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-}-2-carboxylate
[0060] 1H NMR: 1.0 (2H, m), 1.38 (2H, m), 1.51 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.31 (3H,
s), 3.4 (2H, t, J = 11.42), 3.83 (3H, s), 3.9 (2H, dd, J = 4.56 & 12.15 Hz), 4.2 (
2H, t, J = 6.4 7), 7.22 (1H, m), 7.6 (1H, m), 7.8 (1H, d, J = 8.1 Hz), 8.6 (1H, d,
J = 4.71 Hz).
Yield: 49 %
Example 28
Methyl-{2-methyl-5-[4-(1-pyridin-3-yl-ethylideneaminooxy)-butyl-[1,3]dioxane-}-2-carboxylate
[0061] 1H NMR: 1.0 (2H, m), 1.4 (2H, m), 1.51 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.23 (3H,
s), 3.4 (2H, t, J = 11.4Hz), 3.83 (3H, s), 3.9 (2H, dd, J = 4.6 & 12.0 Hz), 4.2 (
2H, t, J =6.47), 7.29 (1H, m), 7.96 (1H, dd, J =1.7 &7.9 Hz), 8.57 (1H, d, J = 4.7Hz),
8.86 (1H, s).
Yield: 39 %
Example 29
Methyl-{2-methyl-5-[4-(1-pyridin-4-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-}-2-carboxylate
[0062] 1H NMR: 1.0 (2H, m), 1.35 (2H, m), 1.51 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.19 (3H,
s), 3.4 (2H, t, J = 11.73 Hz), 3.82 (3H, s), 3.9 (2H, dd, J = 4.44 & 11.79 Hz), 4.2
(2H, t, J =6.4 Hz), 7.5 (2H, d, J = 6.0 Hz), 8.6 (2H, d, J = 6.0Hz). Yield: 38 %
Example 30
Methyl-5-[4-(1-benzo[1,3]dioxoy-5-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]diogane-2-carboxylate
[0063] 1H NMR: 1.03-1.11 (2H, m), 1.31-1.39 (2H, m), 1.51 (3H, s), 1.63-1.70 (2H, m), 2.04
(1H, m), 2.16 ( 3H, s), 3.40 (2H, t, J=11.61 Hz), 3.83 (3H, s), 3.96 (2H, dd, J= 12.06
& 4.65 Hz), 4.13 (2H, t, J= 6.42 Hz), 5.97 (2H, s) 6.79 ( 1H, d, J= 8.1 Hz), 7.08
(1H, dd, J=8.1 & 2.22 Hz), 7.19 (1H, d, J=1.65 Hz). Yield: 54 %
Example 31
Methyl-2-methyl-5-[4-(1-thiophen-2-yl-ethylideneaminoogy)-butyl]-[1,3]dioxane-2-carboxylate
[0064] 1H NMR: 1.03-1.11 (2H, m), 1.34-1.42 (2H, m), 1.51 (3H, s), 1.62-4.72 (2H, m) 2.04
(1H, m), 2.22 (3H, s), 3.40( 2H, t, J=11.41 Hz), 3.83 (3H, s), 3.97 (2H, dd, J=12
& 4.62 Hz), 4.21 (2H, t, J=6.39 Hz), 7.00 (1H, dd, J =5.07 & 3.75 Hz), 7.20 (1H, dd,
J=4.56 &.1.05 Hz), 7.24 (1H, m). Yield: 46 %
Example 32
Methyl-5-[4-(1-benzofuran-2-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylate
[0065] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.1 Hz), 3.8 (3H, s), 4.0 (2H, dd, J=12.1 & 4.6 Hz), 4.2 (2H, t, J=6.5
Hz), 6.9 (1H, s), 7.2-7.3 (2H, m), 7.5 (2H, m). Yield: 39 %
Example 33
Methyl-5-[5-(1-benzofuran-2-yl-ethylideneaminooxy)-pentyl]-2-methyl-[1,3]dioxane-2-carboxylate
[0066] 1H NMR: 1.0 (2H, m), 1.4 (4H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.7 Hz), 3.8 (3H, s), 3.9 (2H, dd, J=12.0 & 4.6 Hz), 4.2 (2H, t, J=6.6
Hz), 6.9 (1H, s), 7.2-7.3 (2H, m), 7.5 (2H, m). Yield: 62 %
Example 34
Methy-5-{4-[1-(2,3-dimethyl-benzofuran-6-yl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0067] 1H NMR: 1.06 (2H, m), 1.41 (2H, m), 1.57 (3H, s),1.74 (2H, m), 2.05 (1H, m), 2.14 (3H,
s), 2.26 (3H, s), 2.38 (3H, s), 3.40 (2H, t, J=11.53 Hz), 3.83 (3H, s), 3.97 (2H,s),
4.17 (2H, t, J=6.13 Hz), 7.35 (1H,d,J=8.1 Hz), 7.51 (1H, d, J= 8.01 Hz), 7.62 (1H,
s).
Yield: 39 %
Example 35
Methyl-2-methyl-5-{4-[1-(1-methyl-1H-indol-3-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate
[0068] 1H NMR: 1.05-1.13 (2H, m), 1.35-1.46 (2H, m), 1.50 (3H, s), 1.70-1.77 (2H, m), 2.05
(1H, m), 2.23 (3H, s), 3.40 (2H, t, J=11.46 Hz), 3.79 (3H, s), 3.82 (3H, s), 3.97
(2H, dd, J=11.95 & 4.032 Hz), 4.19 (2H, t, J=6.42 Hz), 7.17-7.31(4H, m), 8.27(1H,
d, J=7.71 Hz).
Yield: 47 %
Example 36
Methyl-2-methyl-5-[5-(1-naphthalen-2-yl-ethylideneaminooxy)-pentyl]-[1,3]dioxane-2-carboxylate
[0069] 1H NMR: 1.06 (2H, m), 1.25-1.41 (4H, m), 1.51 (3H, s), 1.73 (2H, m), 2.04 (1H, m),
2.32 (3H, s), 3.40 (2H, t, J=11.76 Hz), 3.82 (3H, s), 3.96 (2H, dd, J=12.06 & 4.59
Hz), 4.21 (2H, t, J=6.57 Hz), 7.47 (2H, m), 7.78-7.92 ( 4H, m), 7.98 (1H, s). Yield:
33 %
Example 37
Methyl-2-methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate
[0070] 1H NMR: 1.06-1.14 (2H, m), 1.40 (2H, m), 1.51 (3H, s), 1.71-1.75 (2H, m) 2.06 (1H,
m), 2.33 (3H, s), 3.37-3.51 ( 2H, t, J=11.6 Hz), 3.82 (3H, s), 4.00 (2H, q, J=11.91
& 4.56 Hz), 4.21 (2H, t, J=6.39 Hz), 7.48 (2H, m), 7.79-7.92 (4H, m), 7.99 ( 1H, m).
Yield: 52 %
Example 38
Methyl-2-methyl-5-{4-[1-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylate
[0071] 1H NMR: 1.06- 1.11 (2H, m), 1.38 (2H, m), 1.51 (3H, s), 1.68 (2H, m), 1.76-1.81(4H,
m), 2.04 (1H, m), 2.18 ( 3H, s), 2.77 (4H,m ), 3.40 (2H, t, J=11.61 Hz), 3.83 (3H,
s), 3.96 (2H, dd, J= 11.91 & 4.47 Hz), 4.14 (2H, t, J= 6.45 Hz), 7.03-7.06( 1H, d,
J= 7.74 Hz), 7.32-7.35 (2H, m). Yield: 50 %
Example 39
Methyl-5-{4-[1-(4-methoxymethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0072] 1H NMR: 1.09 (2H, m), 1.34-1.39 (2H, m), 1.51 (3H, s), 1.66-1.71 (2H, m) 2.04 (1H,
m), 2.18 (3H, s), 3.40 (2H, t, J=11.8 Hz), 3.47 (3H, s), 3.83 (3H, s), 3.96 (2H, dd,
J=12.06 & 4.65 Hz), 4.13 (2H, t, J=6.45 Hz), 5.19 (2H, s), 6.99-7.04 (2H, m) 7.54-7.58
(2H, m)
Yield: 47 %
Example 40
Methyl-5-{4-[1-(4-hydroxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0073] To a solution of Methyl-5-{4-[1-(4-methoxymethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
(prepared as per example 39) (1.5 g) in isopropyl alcohol was added concentrated hydrochloric
acid and the reaction mixture was stirred at 50 ° C for about 20 hours. Reaction mixture
was cooled to ambient temperature and solvent was evaporated under reduced pressure
on a rotavapor. Water was added to the residue and extracted with ethyl acetate. The
combined organic extract was washed with water, brine solution, dried over sodium
sulphate and evaporated under reduced pressure on a rotavapor. Crude product was flash
chromatographed over silica gel using 15 % ethyl acetate in petroleum ether as eluent
to obtain 200 mg of pure product.
[0074] 1H NMR: 1.04-1.11 (2H, m), .1.32-1.42 (2H, m), 1.51 (3H, s), 1.63-1.70 (2H, m) 2.04
(1H, m), 2.18 (3H, s), 3.40 (2H, t, J=11.8 Hz), 3.83 (3H, s), 3.96 (2H, dd, J=12.06
&4.68 Hz), 4.13 (2H, t, J=6.42 Hz), 6.81 (2H, dd, J= 6.69 & 2.01 Hz), 7.54 (2H, dd,
J=6.69 & 1.95 Hz). Yield: 15 %
Example 41
Methyl-5-{4-[1-(4-methanesulfonyloxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
[0075] To an ice cold solution of Methyl-5-{4-[1-(4-hydroxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylate
(prepared as per example 40) (200 mg) in anhydrous dichloromethane were added triethyl
amine (82 mg) and methane sulfonyl chloride (75 mg) and the reaction mixture was stirred
at the same temperature for about an hour. Reaction mixture was diluted with dichloromethane,
washed with water, dried over sodium sulphate and evaporated under reduced pressure
on a rotavapor. Crude product was flash chromatographed over silica gel using 20 %
ethyl acetate in petroleum ether as eluent to obtain 200 mg of pure product.
[0076] 1H NMR: 1.04-1.12 (2H, m), 1.34-1.42 (2H, m), 1.51 (3H, s), 1.56-1.71 (2H, m) 2.04
(1H, m), 2.21 (3H, s), 3.14(3H, s),3.40 (2H, t, J=11.8 Hz), 3.83 (3H, s), 3.96 (2H,
dd, J=12.06 & 4.68 Hz), 4.16 (2H, t, J=6.48 Hz), 7.27-7.29 (2H, m), 7.67-7.70 (2H,
m).
Yield: 83 %
Example 42
2-Methyl-5-[4-(1-phenyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
[0077] To a solution of. Methyl-2-methyl-5-[4-(1-phenyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate
(prepared as per example 1) (1.38 g) in a mixture of tetrahydrofuran and methanol
was added another solution of LiOH.H
2O (332 mg) in water and the reaction mixture was stirred at ambient temperature for
about 18 hours. Solvent was evaporated under reduced pressure, water was added to
the residue, acidified with IN HCl to pH 6 and extracted with ethyl acetate. The combined
organic extract was washed with water, brine solution, dried over sodium sulphate
and evaporated under reduced pressure. Crude product was chromatographed (flash) over
silica-gel using 25 % ethyl acetate in hexane as an eluent to obtain 1 g of pure product.
1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.5 Hz), 4.0 (2H, dd, J=12.0 & 4.5 Hz), 4.1 (2H, t, J=6.4 Hz), 7.3
(3H, m), 7.6 (2H, m). Yield: 79%
[0078] The following compounds are prepared by procedure similar to that described in example
42 with appropriate variations of reactants, reaction conditions and quantities of
reagents.
Example 43
5-(4-Benzylideneaminooxy-butyl)-2-methyl-[1,3]dioxane-2-carboxylic acid
[0079] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.73 (2H, m), 2.0 (1H, m), 3.4 (2H,
t, J=1.6 Hz), 4.0 (2H, dd, J=11.9 & 4.5 Hz), 4.1 (2H, t, J=6.4 Hz), 7.3 (3H, m), 7.5
(2H, m), 8.0 (1H, s). Yield: 96 %
Example 44
2-Methyl-5-{4-[1-(4-trifluoromethyl-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0080] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.6 Hz), 4.0 (2H, dd, J=12.0 & 4.7 Hz), 4.1 (2H, t, J=6.4 Hz), 7.6
(2H, t, J=8.2 Hz), 7.7 (2H, d, J=8.0 Hz). Yield: 97 %
Example 45
5-{4-[1-(4-Fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0081] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.4 (2H, t, J=11.6 Hz), 4.0 (2H, dd, J=11.9 & 4.5 Hz), 4.1 (2H, t, J=6.4 Hz), 7.0
(2H, t, J=8.6 Hz), 7.6 (2H, m). Yield: 83 %
Example 46
5-{4-[1-(4-Chloro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0082] 1H NMR: 1.1 (2H, m), 1.3 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.5 (2H, t, J=11.5 Hz), 4.0 (2H, m), 4.1 (2H, t, J=6.3 Hz), 7.3 (2H, d, J=8.5 Hz),
7.6 (2H, d, J=8.5 Hz). Yield: 79 %
Example 47
5-{4-[1-(4-Methanesulfonyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0083] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.0 (3H, s), 3.4 (2H, t, J=11.6 Hz), 4.0 (2H, dd, J=11.9 & 4.4 Hz), 4.2 (2H, t, J=6.4
Hz), 7.8 (2H,d, J=8.5 Hz), 7.9 (2H, d, J=8.5 Hz). Yield: 80 %
Example 48
2-Methyl-5-[4-(1-p-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
[0084] 1H NMR: 1.07-1.14 (2H, m), 1.33-1.41 (2H, m), 1.52 (3H, s), 1.64-1.72 (2H, m) 2.05
(1H, m), 2.19 (3H, s), 2.35 (3H, s), 3.47 (2H, m), 3.99 (2H, dd, J=12.03 & 4.56 Hz),
4.15 (2H, t, J=6.45 Hz), 7.16 (2H, d, J =8.07 Hz), 7.52 (2H, d, J=8.19 Hz). Yield:
22 %
Example 49
5-{4-[1-(3-Chloro-4-fluoro-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0085] 1H NMR: 1.07-1.15 (2H, m), 1.35 (2H, m), 1.56 (3H, s), 1.65-1.71 (2H, m), 2.05 (1H,
m), 2.18 (3H, s), 3.43-3.57 (2H, m), 3.99 (2H, dd, J=11.48 & 4.56 Hz), 4.16 (2H, t,
J=6.42 Hz), 7.12 (1H, m), 7.47-7.69 (1H, m), 7.70 (1H, dd, J=7.08 & 2.16 Hz).
Yield: 89 %
Example 50
5-{4-[1-(4-Butyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0086] 1H NMR: 0.91 (3H, t, J=7.29Hz), 1.12 (2H, m), 1.36 (4H, m), 1.56-1.61(5H, s), 1.69
(2H, m), 2.04 (1H, m), 2.17 (3H, s), 2.61 (2H, ,t, J=7.53 Hz), 3.46 (2H, t, J=11.46
Hz), 3.99 ( 2H, dd, J=11.88 & 4.5 Hz), 4.15 (2H, t, J=6.33 Hz), 7.16 (2H, d, J=8.07
Hz), 7.53 (2H, d, J=8.04 Hz). Yield: 98 %
Example 51
2-Methyl-5-{4-[1-(4-methylsulfanyl-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0087] 1H NMR: 1.07-1.15 (2H, m), 1.33-1.43 (2H, m), 1.57 (3H, s), 1.65-1.72 (2H, m) 2.06
(1H, m), 2.19 (3H, s), 2.49(3H, s), 3.46 (2H, t, J= 11.52 Hz), 3.99 (2H, dd, J=12.06
& 4.68 Hz), 4.15 (2H, t, J=6.42 Hz), 7.22 (2H, d , J =8.46 Hz), 7.54-7.57 (2H, d,
J=8.43 Hz). Yield: 76 %
Example 52
5-{4-[1-(4-Ethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0088] 1H NMR: 1.09-1.14 (2H, m), 1.22 (3H, t, J= 7.59 Hz),1.38 (2H, m), 1.56 (3H, s), 1.64-1.74
(2H, m), 2.05 (1H, m), 2.20 (3H, s), 2.63 (2H, q, J= 15.06 & 7.53 Hz), 3.46 (2H, t,
J=10.2 Hz), 3.99 (2H, dd, J=11.46 & 4.23 Hz), 4.15 (2H, t, J=6.36 Hz), 7.18 (2H, d,
J= 8.07 Hz), 7.54 (2H, d, J= 8.16 Hz). Yield: 91 %
Example 53
5-{4-[1-(3,4-Dimethyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0089] 1H NMR: 1.07-1.14 (2H, m), 1.35-1.42 (2H, m), 1.56 (3H, s), 1.67-1.71 (2H, m), 2.05
(1H, m), 2.19 (3H, s), 2.26 (3H, s), 2.27 (3H, s), 3.46 (2H, t, J=10.2 Hz), 3.99 (2H,
dd, J=11.46 & 4.23 Hz), 4.15 (2H, t, J=6.42 Hz), 7.12 (1H, d, J= 7.83 Hz), 7.32-7.36
(1H, m), 7.60 (1H, m). Yield: 84 %
Example 54
5-{5-[1-(3,4-Dimethyl-phenyl)-ethylideneaminooxy]-pentyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0090] 1H NMR: 1.05-1.10 (2H, m), 1.28-1.38 (4H, m), 1.56 (3H, s), 1.69 (2H, m), 2.03 (1H,
m), 2.19 (3H, s), 2.26 (3H, s), 2.27 (3H, s), 3.45 (2H, t, J=11.8 Hz), 3.99 (2H, dd,
J=11.96 & 4.53 Hz), 4.15 (2H, t, J=6.51 Hz), 7.12 (1H, d, J=7.86 Hz), 7.33 (1H, d,
J=7.98 Hz), 7.41 (1H, s). Yield: 89 %
Example 55
5-{4-[1-(4-Ethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0091] 1H NMR: 1.06-1.14 (2H, m), 1.25-1.43 (5H, m),1.56 (3H, s), 1.68 (2H, m), 2.04 (1H,
m), 2.18 (3H, s), 3.46 (2H, t, J=11.52 Hz), 3.96-4.08 (4H, m), 4.13 (2H, t, J=6.39
Hz), 6.86 (2H, d, J= 8.79 Hz), 7.56 (2H, d, J=8.79 Hz). Yield: 90 %
Example 56
5-{4-[1-(4-Isopropoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0092] 1H NMR: 0.86 (2H, m), 1.06-1.24 (8H, m), 1.56 (3H, s), 1.66 (2H, m), 2.04 (1H, m),
2.18 (3H, s), 3.46 (2H, t, J=10.59 Hz), 3.96 (2H, dd, J=11.70 & 4.56 Hz), 4.13 (2H,
t, J= 6.36 Hz), 4.56 (1H, m), 6.86 (2H, d, J= 8.58 Hz), 7.56 (2H, d, J=8.58 Hz). Yield:
87 %
Example 57
5-{4-[1-(4-Methoxy-3-methyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0093] 1H NMR: 1.09-1.14 (2H, m), 1.35-1.43 (2H, m), 1.56 (3H, s), 1.64-1.74 (2H, m), 2.05
(1H, m), 2.18 (3H, s), 2.22 (3H, m), 3.46 (2H, t, J=10.32 Hz), 3.84 (3H, s), 3.99
(2H, dd, J=11.88 & 4.50 Hz), 4.14 (2H, t, J=6.39 Hz), 6.80 (1H, d, J= 8.46 Hz), 7:44
(1H, dd, J= 8.46 & 2.06 Hz), 7.45 (1H, m). Yield: 82 %
Example 58
2-Methyl-5-{4-[1-(4-phenoxy-phenyl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0094] 1H NMR: 1.09-1.14 (2H, m), 1.36-1.41 (2H, m); 1.56 (3H, s), 1.65-1.74 (2H, m), 2.05
(1H, m), 2.20 (3H, s), 3.46 (2H, m), 3.99 (2H, dd, J=12.03 & 4.59 Hz), 4.15 (2H, t,
J=6.39 Hz), 6.97-7.035(4H, m), 7.12 (1H, d, J=7.35 Hz), 7.33 (2H, m), 7.60 (2H, d,
J=6.81 & 2.01 Hz). Yield: 78 %
Example 59
5-{4-[1-(3,4-Dimethoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0095] 1H NMR: 1.09-1.15 (2H, m), 1.36-1.41 (2H, m), 1.56 (3H, s), 1.67-1.72 (2H, m) 2.05
(1H, m), 2.19 (3H, s), 3.46 (2H, t, J= 11.58 Hz), 3.89 (3H, s), 3.92 (3H, s), 3.99
(2H, dd, J=12.06 & 4.50 Hz), 4.15 (2H, t, J=6.42 Hz), 6.85 (1H, d, J=8.4 Hz), 7.13
(1H, dd, J= 8.37& 2.04 Hz), 7.27(1H, d, J= 2.01Hz). Yield: 81 %
Example 60
5-{4-[1-(4-Isobutyl-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0096] 1H NMR: 0.88 (3H, s), 0.90 (3H, s), 1.09-1.14 (2H, m), 1.38 ((2H, m) ,1.56 (3H, s),
1.62 (2H, m), 1.85 (1H, m) 2.01 (1H, m), 2.20 (3H, s), 2.47 (2H,d, J=7.17 Hz), 3.46
(2H, t, J=9.48 Hz), 3.99 (2H, dd, J=12.06 & 4.56 Hz), 4.15 (2H, t, J=6.45 Hz), 7.12
(2H, d, J=8.28 Hz), 7.53 (2H, d, J=8.16 Hz). Yield: 97 %
Example 61
5-{4-[1-(3-Fluoro-4-methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-1-carboxylic
acid
[0097] 1H NMR: 1.07-1.14 (2H, m), 1.33-1.40 (2H, m), 1.56 (3H, s), 1.64-1.73 (2H, m), 2.05
(1H, m), 2.17 (3H, s), 3.46 (2H, t, J=11.51), 3.90 (3H, s), 3:99 (2H, dd, J=12.06
& 4.59 Hz), 4.14 (2H, t, J=6.42 Hz), 6.91 (1H, m), 7.31-7.35 (1H, m), 7.42-7.47 (1H,
dd, J=12.75 & 2.13 Hz). Yield: 90 %
Example 62
2-Methyl-5-[5-(1-naphthalen-2-yl-ethylideneaminooxy)-pentyl]-[1,3]dioxane-2-carboxylic
acid
[0098] 1H NMR: 1.03-1.10 (2H, m), 1.32-1.40 (4H, m),1.55 (3H, s), 1.71 (2H, m), 2.04 (1H,
m), 2.32 (3H, s), 3.49 (2H, t, J=7.92 Hz), 3.98 (2H, dd, J=11.64 & 4.38 Hz), 4.21
(2H, t, J=6.54 Hz), 7.45-7.50 (2H, m), 7.77-7.91 (4H, m), 7.98 (1H, s). Yield: 53
%
Example 63
2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0099] 1H NMR: 1.09-1.16 (2H, m), 1.36-1.46 (2H, m), 1.57 (3H, s), 1.69-1.78 (2H, m) 2.07
(1H, m), 2.33 (3H, s), 3.47 (2H, t, J=11.16 Hz), 4.0 (2H, dd, J=11.82 & 4.68 Hz),
4.21 (2H, t, J=6.36 Hz), 7.48 (2H, dd , J =6.12 & 3.21 Hz), 7.78-7.91 (4H, m), 7.99
( 1H, m). Yield: 82 %
Example 64
2-Methyl-5-{4-[1-(5,6,7,8-tetrahydro-naphthalen-2-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0100] 1H NMR: 1.09-1.14 (2H, m), 1.35-1.40 (2H, m), 1.56 (3H, s), 1.64-1.71 (2H, m), 1.76-1.81
(4H,m), 2.05 (1H, m), 2.18 (3H, s), 2.77 (4H, m), 3.46 (2H, t, J= 11.55 Hz), 3.99
(2H, dd, J=12.00 & 4.67 Hz), 4.14 (2H, t, J=6.45 Hz), 7.03-7.06 (1H, d, J=7.8 Hz),
7.32 (1H, s), 7.34 (1H, s). Yield: 77 %
Example 65
5-{4-[1-(4-Hydroxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0101] 1H NMR: 0.85 (2H, m), 1.25 (2H, m) ,1.52 (3H, s), 1.67 (2H, m), 2.04 (1H, m), 2.16
(3H, s), 3.51(2H, t, J=11.70 Hz), 3.94 (2H, dd, J=11.88 & 4.5 Hz), 4.11 (2H, t, J=6.42
Hz), 6.82 (2H, d, J= 8.7 Hz), 7.49 (2H, m). Yield: 90 %
Example 66
5-{4-[1-(4-Methoxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0102] 1H NMR: 1.06-1.14 (2H, m), 1.33-1.43 (2H, m), 1.56 (3H, s), 1.64-1.71 (2H, m) 2.05
(1H, m), 2.18 (3H, s), 3.46 (2H, t, J= 11.52 Hz), 3.82 (3H, s), 3.99 (2H, dd, J=12.06
& 4.68 Hz), 4.13 (2H, t, J=6.42 Hz), 7.85-6.90 (2H, m), 7.55-7.60 (2H, m). Yield:
94 %
Example 67
5-{4-[1-(4-Methanesulfonyloxy-phenyl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0103] 1H NMR: 1.13 (2H, m), 1.33-1.43 (2H, m), 1.56 (3H, s), 1.65-1.72 (2H, m) 2.01 (1H,
m), 2.19 (3H, s), 3.16 (3H, s), 3.40-3.49 (2H, m), 3.99 (2H, dd, J=12.06 & 4.68 Hz),
4.18 (2H, t, J=5.04 Hz), 7.29-7.39 (2H, m), 7.68-7.71 (2H, d, J= 6.78 & 2.01 Hz).
Yield: 34 %
Example 68
2-Methyl-5-[4-(1-thiophen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0104] 1H NMR: 1.09-1.12 (2H, m), 1.38 (2H, m), 1.57 (3H, s), 1.65-1.70 (2H, m) 2.07 (1H,
m), 2.33 (3H, s), 3.47(2H, t, J=11.37 Hz), 4.0 (2H, dd, J=11.85 & 4.05 Hz), 4.13 (2H,
t, J=6.33 Hz), 7.01 (1H, m), 7.19-7.24 (2H, m). Yield: 85 %
Example 69
5-[4-(1-Benzo[1,3]dioxol-5-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0105] 1H NMR:1.07-1.14 (2H, m), 1.35-1.43 (2H, m), 1.57 (3H, s), 1.60-1.71 (2H, m), 2.05
(1H, m), 2.17 (3H, s), 3.47 (2H, t, J= 11.15 Hz), 3.99 (2H, dd, J=12.03 & 4.59 Hz),
4.13 (2H, t, J=6.39 Hz), 5.97 (2H, s), 6.79 (1H, d,J=8.16 Hz), 7.08 (1H, dd, J=8.1
& 1.77 Hz), 7.20 (1H, d, J=1.68 Hz). Yield: 84 %
Example 70
5-[4-(1-Biphenyl-4-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0106] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.5 (2H, t, J=11.4 Hz), 4.0 (2H, dd, J=11.5 & 3.9 Hz), 4.2 (2H, t, J=6.3 Hz), 7.3
(1H, m), 7.4 (2H, m), 7.6 (4H, m), 7.7 (2H, m). Yield: 74 %
Example 71
2-Methyl-5-[4-(1-phenyl-pentylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
[0107] 1H NMR: 0.93 (3H, t, J=7.2 Hz), 1.1 (2H, m), 1.4 (4H, m), 1.5 (2H, m), 1.57 (3H, s),
1.7 (2H, m), 2.0 (1H, m), 2.7 (2H, t, J=7.4 Hz), 3.4 (2H, t, J=11.4 Hz), 4.0 (2H,
dd, J=11.8 & 4.5 Hz), 4.1 (2H, t, J=6.3 Hz), 7.3 (2H, m), 7.6 (3H, m). Yield: 96 %
Example 72
5-[4-(1-Benzofuran-2-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0108] 1H NMR: 1.1 (2H, m), 1.4 (2H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.5 (2H, t, J=11.6 Hz), 4.0 (2H, dd, J=11.9 & 4.5 Hz), 4.2 (2H, t, J=6.4 Hz), 6.9
(1H, s), 7.2-7.3 (2H, m), 7.5 (2H, m). Yield: 50 %
Example 73
5-[5-(1-Benzofuran-2-yl-ethylideneaminooxy)-pentyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0109] 1H NMR:1.0 (2H, m), 1.4 (4H, m), 1.5 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.2 (3H, s),
3.45 (2H, t, J=11.5 Hz), 4.0 (2H, dd, J=11.7 & 4.4 Hz), 4.2 (2H, t, J=6.5 Hz), 6.9
(1H, s), 7.2-7.3 (2H, m), 7.5 (2H, m). Yield: 95 %
Example 74
5-{4-[1-(2,3-Dimethyl-benzofuran-6-yl)-ethylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylicacid
[0110] 1H NMR: 1.10-1.154 (2H, m), 1.23-1.26 (2H, m), 1.56 (3H, s), 1.66-1.73 (2H, m), 2.04
(1H, m), 2.14 (3H, s), 2.26 (3H, s), 2.38 (3H, s), 3.47 (2H, m), 4.00 (2H, dd, J=11.5028
& 4.068 Hz), 4.17 (2H, t, J=6.13 Hz), 7.35 (1H,d,J=8.1 Hz), 7.51 (1H, d, J= 8.01 Hz),
7.62 (1H, s). Yield: 30 %
Example 75
2-Methyl-5-{4-[1-(1-methyl-1H-indol-3-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0111] 1H NMR: 1.08-1.23 (2H, m), 1.39-1.44 (2H, m), 1.55 (3H, s), 1.70-1.77 (2H, m), 2.05
(1H, m), 2.24 (3H, s), 3.46 (2H, t, J=11.52 Hz), 3.79 (3H, s), 3.97 (2H, dd, J=11.95
& 4.032 Hz), 4.19 (2H, t, J=6.39 Hz), 7.17-7.36 (4H, m), 8.27(1H, d, J=7.8 Hz).
Yield: 90 %
Example 76
2-Methyl-5-[4-(1-m-tolyl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
[0112] 1H NMR: 1.10 (2H, m), 1.38 (2H, m), 1.57 (3H, s), 1.67 (2H, m), 2.0 (1H, m), 2.21 (3H,
s), 2.37(3H, s), 3.47 (2H, t, J = 11.03 Hz), 4.0 (2H, dd, J = 4.5 & 12.03 Hz), 4.16
(2H, t. J = 6.39 Hz), 7.15 - 7.27 ( 2H, m), 7.4 ( 2H, m). Yield: 75 %
Example 77
5-{4-[1-(4-Methoxy-phenyl)-propylideneaminooxy]-butyl}-2-methyl-[1,3]dioxane-2-carboxylic
acid
[0113] 1H NMR: 1.1 (5H, m), 1.38 (2H, m), 1.56 (3H, s), 1.68 (2H, m), 2.05 (1H, m), 2.71 (2H,
q, J = 7.57 Hz), 3.46 (2H, t, J = 11.58 Hz), 3.82 (3H, s), 4.0 (2H, dd, J = 4.5 &
11.92 Hz), 4.12 (2H, t. J = 6.33 Hz), 6.89 ( 2H, d, J = 8.8 Hz), 7.55 ( 2H, d, J =
8.8 Hz). Yield: 85 %
Example 78
2-Methyl-5-[4-(1-p-tolyl-propylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic acid
[0114] 1H NMR: 1.1 (5H, m), 1.38 (2H, m), 1.57 (3H, s), 1.69 (2H, m), 2.0 (1H, m), 2.35 (3H,
s), 2.7(2H, q. J = 7.5 Hz), 3.47 (2H, t, J = 11.58 Hz), 3.98 (2H, dd, J = 4.44 & 11.88
Hz), 4.13 (2H, t. J = 6.33 Hz), 7.15 ( 2H, d, J = 8.0 Hz), 7.52 ( 2H, d, J = 8.1 Hz).
Yield: 91 %
Example 79
2-Methyl-5-[4-(1-pyridin-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0115] 1H NMR: 0.94 (2H, m), 1.26 (3H, s), 1.28 (2H, m), 1.57 - 1.72 (3H, m), 2.20 (3H, s),
3.53 (2H, t, J = 11.14Hz), 3.63 (2H, dd, J = 4.9 & 11.18 Hz), 4.12 ( 2H, t, J = 6.41Hz),
7.39 (1H, m), 7.8 (2H, m), 8.58 (1H, d, J = 4.66 Hz). Yield: 74 %
Example 80
2-Methyl-5-[4-(1-pyridin-3-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0116] 1H NMR: 1.10 (2H, m), 1.41 (2H, m), 1.58 (3H, s), 1.67 (2H, m), 2.07 (1H, m), 2.22
(3H. s), 3.58 (2H, t, J = 11.58 Hz), 4.0 (2H, dd, J = 4.5 & 11.76 Hz), 4.21 (2H, t,
J = 6.2 Hz), 4.46 (1H, bs), 7.4 ( 1H, t, J = 5.1Hz), 8.0 (1H, d, J = 7.95 Hz), 8.60
(1H, m), 8.95 (1H,s). Yield: 98 %
Example 81
2-Methyl-5-[4-(1-pyridin-4-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0117] 1H NMR: 1.10 (2H, m), 1.37 (2H, m), 1.54 (3H, s), 1.7 (2H, m), 2.0 (1H, m), 2.20 (3H,
s), 3.53 (2H, t, J = 11.64 Hz), 3.97 (2H, dd, J = 4.5 & 11.64 Hz), 4.2 (2H, t. J =
6.27Hz), 7.57 ( 2H, s), 8.62 ( 2H, s). Yield: 67 %
Example 82
2-Methyl-5-{4-[1-(5-methyl-furan-2-yl)-ethylideneaminooxy]-butyl}-[1,3]dioxane-2-carboxylic
acid
[0118] 1H NMR: 0.57-1.13 (2H, m), 1.37 (2H, m), 1.55 (3H, s), 1.67 (2H, m), 2.00 (1H, m),
2.01 (3H, s), 2.34 (3H, s), 3.46 (2H, ,t, J=9.27 Hz), 3.99 ( 2H, dd, J=11.61 & 4.5
Hz), 4.15 (2H, m), 6.01 (1H, d, J=2.37 Hz), 6.49 (1H, d, J=3.18 Hz). Yield: 55 %.
Example 83
Octyl-2-methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylate
[0119] A mixture of 2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid (prepared as per example 63) (0.9 g), n-octyl bromide (0.6 mL) and potassium
carbonate (0.64 g) in anhydrous dimethyl formamide (10 mL) was stirred at 60 ° C for
about 8 hours in an inert atmosphere. The reaction mixture was cooled to ambient temperature,
poured into ice cold water and extracted with ethyl acetate. The combined organic
extract was washed with water, brine solution, dried over sodium sulphate and evaporated
under reduced pressure. Crude product was flash chromatographed over silica gel 8
% ethyl acetate in petroleum ether as eluent to obtain 1 g of pure product.
1H NMR: 0.87 (3H, t, J=6.0 Hz), 1.12 (2H, m), 1.27-1.43 (12H, m), 1.50 (3H, s), 1.72
(4H, m), 2.04 (1H, m), 2.33 (3H, s), 3.42 (2H, t, J=11.61 Hz), 3.99 (2H, dd, J=11.88
& 4.5 Hz), 4.23 (4H, t, J=1.71 Hz), 7.46-7.51 (2H, m), 7.78-7.92 (4H, m), 7.98 (1H,
s).
Yield: 86 %
Example 84
Sodium salt of 2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0120] To a solution of 2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid (prepared as per Example 63) (400 mg) in methanol was added sodium methoxide
(56 mg) and stirred at 30 °C for 0.5 hour. Solvent was evaporated under reduced pressure
on a rotavapor, residue was triturated with diethyl ether, filtered and dried under
vacuum to yield 180 mg of salt.
Example 85
L-Arginine salt of 2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid
[0121] To a suspension of 2-Methyl-5-[4-(1-naphthalen-2-yl-ethylideneaminooxy)-butyl]-[1,3]dioxane-2-carboxylic
acid (prepared in example 63) (1 g) in ethanol was added a solution of L-Arginine
(451 mg) in water and the reaction mixture was refluxed for 8 hours. Reaction mixture
was cooled to 30 °C and solid separated was filtered and dried under vacuum to obtain
400 mg of the salt.
Example 86
Calcium salt of 5-[4-(1-Benzofuran-2-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxrylic
acid
[0122] 5-[4-(1-Benzofuran-2-yl-ethylideneaminooxy)-butyl]-2-methyl-[1,3]dioxane-2-carboxylic
acid (prepared as per example 72) (3 g) was added to a solution of sodium methoxide
(prepared by adding 184 mg of sodium metal to 20 mL of dry methanol) and stirred for
0.5 hour. To this was added a solution of calcium acetate (632 mg) in water. Solid
precipitated was filtered and dried under vacuum to yield 3 g of salt. In like manner
salts in the table 1 were prepared following the procedure described for the examples
84-86. Following similar process, salts for the other compounds may also be prepared.
Table 1
Example No. |
Free-acid example No. |
Salt prepared |
Melting Point (°C)* |
84 |
63 |
Na |
240 |
85 |
63 |
L-Arginine |
230 (decomposed) |
86 |
72 |
Ca |
250 (decomposed) |
87 |
72 |
L-Arginine |
212 |
88 |
53 |
Ca |
250 |
89 |
53 |
L-Arginine |
200 |
90 |
75 |
L-Arginine |
224 |
* The melting points were uncorrected and may vary in the range of ± 4 °C. |
[0123] The compounds of the present invention lowered triglyceride, total cholesterol, LDL,
VLDL and increased HDL and lowered serum glucose levels. This was demonstrated by
in vitro as well as
in vivo animal experiments.
A) Demonstration of in vitro efficacy of compounds:
[0124] Invitro hPPAR α & hPPARγ activities were determined as per in-house protocols and
the results of representative compounds are provided in table 2 below as a proof of
the efficacies of the novel class of compounds disclosed above.
Table 2
Example No. |
EC50(PPAR alpha) □M |
EC50(PPAR gamma)□M |
44 |
0.08 |
5.1 |
46 |
0.14 |
7.2 |
48 |
0.17 |
15 |
49 |
0.3 |
11.9 |
52 |
0.03 |
4 |
55 |
0.06 |
5.2 |
56 |
0.08 |
2.9 |
57 |
0.04 |
11.4 |
59 |
0.13 |
41.4 |
60 |
0.01 |
0.8 |
61 |
0.05 |
38.8 |
62 |
0.02 |
0.9 |
84 |
0.004 |
1.9 |
64 |
0.004 |
2 |
66 |
0.19 |
8 |
67 |
1.2 |
35 |
68 |
2.7 |
16.5 |
69 |
0.15 |
5.5 |
70 |
- |
0.2 |
76 |
0.1 |
11 |
77 |
0.28 |
3.5 |
78 |
0.08 |
3.9 |
B) Demonstration of in vivo efficacy of compounds:
i) Serum triglyceride lowering activity in Swiss albino mice:
[0125] Male Swiss albino mice (SAM) were bred in Zydus animal house. All these animals were
maintained under 12 hour light and dark cycle at 25±1 °C. Animals were given standard
laboratory chow (NIN, Hyderabad, India) and water ad libitum. SAM of 20-30 g body
weight range was used. The protocol approved by Institutional Animal Ethics Committee
is being used.
[0126] The test compounds were administered orally to Swiss albino mice at 0.001 to 50 mg
/ kg/ day dose for 6 days. The compound was administered after suspending it in 0.25
% CMC or dissolving it in water, when compound is water-soluble. Control mice were
treated with vehicle (0.25 % of Carboxymethyl cellulose; dose 10 ml/kg).
[0127] The blood samples were collected on 0
th day and in fed state 1 hour after drug administration on 6
th day of the treatment. The blood was collected in non heparinised capillary and the
serum was analyzed for triglyceride (
Wieland, O. Methods of Enzymatic analysis. Bergermeyer, H., O., Ed., 1963. 211-214;
Trinder, P. Ann. Clin. Biochem. 1969. 6: 24-27). Measurement of serum triglyceride was done using commercial kits (Zydus-Cadila,
Pathline, Ahmedabad, India).
Formula for calculation:
Percentage reduction in triglycerides was calculated according to the formula:
OC = Zero day control group value OT = Zero day treated group value
TC = Test day control group TT = Test day treated group
Table 3:
Triglyceride lowering activity in Swiss albino mice: |
Example No. |
Dose (mg/kg/day) |
% Triglyceride lowering |
44 |
10 |
40 |
46 |
10 |
39 |
48 |
10 |
64 |
49 |
10 |
51 |
52 |
10 |
36 |
55 |
10 |
46 |
57 |
10 |
43 |
59 |
10 |
22 |
60 |
10 |
62 |
61 |
10 |
44 |
62 |
10 |
69 |
63 |
10 |
84 |
64 |
10 |
85 |
66 |
10 |
50 |
67 |
10 |
75 |
68 |
10 |
33 |
69 |
10 |
61 |
70 |
10 |
49 |
76 |
10 |
67 |
77 |
10 |
39 |
78 |
10 |
42 |
83 |
10 |
61 |
ii) Serum glucose lowering activity in db/db mice models
[0128] Homozygous animal C
57BL/KsJ-db/db mice are obese, hyperglycemic, hyperinsulinemic and insulin resistant
(
J. Clin. Invest., 85, 962-967, 1990), whereas heterozygous are lean and normoglycemic. The homozygous animals very closely
mimic the human type II diabetes when blood sugar levels are not sufficiently controlled.
Since this type of model resembles human type II diabetes mellitus, the compounds
of the invention were tested for their antidiabetic activity in this model.
[0129] The compounds of the present invention showed serum glucose and triglycerides lowering
activities.
[0130] Male C
57 BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 40 to 60 grams,
procured from the Jackson Laboratory, USA, were used in the experiment.
[0131] Test compounds were suspended on 0.25 % carboxymethyl cellulose or dissolved in water
when the compound is water soluble and administered to test group containing 6 animals
at a dose of 0.001 mg to 50 mg/kg through oral gavage daily for 6 days. The control
group received vehicle (dose 10 ml/kg). On the 6
th day, one hour after the drug dosing, blood was collected from retro-orbital sinus
and the serum was analyzed for glucose and triglycerides were measured using commercial
kits (Zydus-Cadila, Pathline, Ahmedabad, India). The serum glucose and triglyceride
lowering activities of the test compound was calculated according of the formula:
OC = Zero day control group value OT = Zero day treated group value
TC = Test day control group TT = Test day treated group
Table 4
Serum glucose & triglycerides lowering activity in db/db mice: |
Example No. |
Dose (mg/kg/day) |
Serum Glucose reduction (%) |
Plasma TG reduction (%) |
48 |
3 |
14 |
44 |
63 |
3 |
41 |
59 |
64 |
3 |
31 |
46 |
66 |
3 |
27 |
45 |
67 |
3 |
12 |
48 |
70 |
3 |
26 |
52 |
[0132] No adverse effects were observed for any of the mentioned compounds of invention.
The compounds of the present invention showed good serum glucose, lipid and cholesterol
lowering activity in the experimental animals used. These compounds are useful for
the testing / prophylaxis of diseases caused by hyperlipidemia, hypercholesterolemia,
hyperinsulinemia, hyperglycemia such as NIDDM, cardiovascular diseases, stroke, hypertension,
obesity since such diseases are interlinked to each other.